Homology Medicines, Inc.
Hedge Funds Holdings
Last updated:
Homology Medicines, Inc.‘s stocks are currently a part of 40 hedge funds’ portfolios, which represents 16.68% of the total amount of its stocks outstanding. This makes up a total of 9.57M shares of Homology Medicines, Inc.. Compared to the previous quarter, the number fell by -54.64% or -11.53M shares fewer. As for the holding position changes, 10% (4) of current hedge fund investors increased the number of shares held, 30% (12) of current holders sold a part of the shares held, and 25% (10) closed the holdings completely. 3 hedge funds are new holders of Homology Medicines, Inc. stock in Q1 2023, it is 7.5% of total holders.
Hedge funds holding Homology Medicines (Q2 2018 – Q1 2023)
| Q2 2018 | 53 |
|---|---|
| Q3 2018 | 50 |
| Q4 2018 | 65 |
| Q1 2019 | 65 |
| Q2 2019 | 85 |
| Q3 2019 | 79 |
| Q4 2019 | 85 |
| Q1 2020 | 89 |
| Q2 2020 | 100 |
| Q3 2020 | 101 |
| Q4 2020 | 103 |
| Q1 2021 | 105 |
| Q2 2021 | 113 |
| Q3 2021 | 113 |
| Q4 2021 | 113 |
| Q1 2022 | 98 |
| Q2 2022 | 78 |
| Q3 2022 | 75 |
| Q4 2022 | 76 |
| Q1 2023 | 40 |
Hedge funds changes in Homology Medicines positions (Q2 2018 – Q1 2023)
| Q2 2018 | 26 | 12 | 10 | 15 | -10 |
|---|---|---|---|---|---|
| Q3 2018 | 7 | 24 | 8 | 10 | 1 |
| Q4 2018 | 19 | 23 | 12 | 4 | 7 |
| Q1 2019 | 8 | 26 | 14 | 8 | 9 |
| Q2 2019 | 29 | 37 | 10 | 6 | 3 |
| Q3 2019 | 14 | 36 | 15 | 20 | -6 |
| Q4 2019 | 19 | 27 | 22 | 8 | 9 |
| Q1 2020 | 18 | 25 | 30 | 12 | 4 |
| Q2 2020 | 24 | 52 | 14 | 13 | -3 |
| Q3 2020 | 23 | 26 | 38 | 20 | -6 |
| Q4 2020 | 18 | 32 | 33 | 16 | 4 |
| Q1 2021 | 17 | 29 | 31 | 14 | 14 |
| Q2 2021 | 26 | 50 | 16 | 18 | 3 |
| Q3 2021 | 15 | 36 | 29 | 14 | 19 |
| Q4 2021 | 20 | 40 | 29 | 20 | 4 |
| Q1 2022 | 11 | 26 | 37 | 26 | -2 |
| Q2 2022 | 18 | 19 | 28 | 34 | -21 |
| Q3 2022 | 10 | 14 | 28 | 14 | 9 |
| Q4 2022 | 15 | 11 | 25 | 14 | 11 |
| Q1 2023 | 3 | 4 | 12 | 10 | 11 |
Hedge funds changes in Homology Medicines stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 24,000 | 0 |
| Q4 2019 | 28,000 | 924,000 |
| Q1 2020 | 329,000 | 930,000 |
| Q2 2020 | 250,000 | 1,400,000 |
| Q3 2020 | 1,979,000 | 2,040,000 |
| Q4 2020 | 659,000 | 2,746,000 |
| Q1 2021 | 806,000 | 1,692,000 |
| Q2 2021 | 322,000 | 1,037,000 |
| Q3 2021 | 1,420,000 | 866,000 |
| Q4 2021 | 793,000 | 369,000 |
| Q1 2022 | 102,000 | 3,423,000 |
| Q2 2022 | 36,000 | 1,104,000 |
| Q3 2022 | 114,000 | 21,000 |
| Q4 2022 | 96,476 | 15,756 |
| Q1 2023 | 417,000 | 1,000 |